SYNTHESIS OF NEW BIS(INDOXYL)METHANES CATALYZED 
BY BENZYL SULFAMIC ACID AND EVALUATION 
OF THEIR ANTIMICROBIAL ACTIVITIES

Sara Soltani,¹ Naser Montazeri,¹,* Masoud Mohammadi Zeydi,¹ 
and Majid M. Heravi²

Original article submitted April 3, 2019.

Benzylsulfamic acid has been prepared and introduced as a new heterogeneous acid catalyst. This reagent was 
used for the synthesis of new bis(indolyl)methanes 3a–3f via reaction of bis-aldehydes 1 with indoles 2 at 
100°C. All reactions were performed under solvent-free conditions with high to excellent yields. The synthe-
sized bis(indolyl)methanes were evaluated for their antibacterial and antifungal activities.

Keywords: bis(indolyl)methanes; benzylsulfamic acid; heterogeneous catalysis; antibacterial activity; 
antifungal activity.

1. INTRODUCTION

The study of bis(indolyl)methanes (BIMs) are one of the 
most active research areas for medicinal chemists because of 
the wide occurrence of BIMs in various natural products pos-
sessing biological activity [1 – 3]. This biological activity in-
cludes anti-inflammatory [4], anti-oxidant [5], antimicrobial 
[6, 7], anticancer [8], antibacterial properties [9], nontoxicity, 
DNA-damaging ability [10], and anti-tumorigenic action 
[11] reported for the indoles, BIMs and their derivatives. 
They are also effective in promoting estrogen metabolism 
and inducing apoptosis of cancer cells in humans [12]. In ad-
dition, a group of indole derivatives used as triplet energy 
materials [13], dyes [14], and colorimetric sensors [15, 16]. 
Because BIMs are important heterocycles in pharmaceutical 
chemistry, it was of interest to study the synthesis and prop-
erties of this group of compounds.

A general approach to the synthesis of bis(indol-3-yl)me-
than es is based on the condensation of indoles with alde-
hydes or ketones in the presence of various catalysts. These 
catalysts can include ionic liquids [17 – 21], heteropolyacids 
[22], acid catalysts such as PEG-SO₂H [23], Ph-PMO-SO₂H 
[24], H₃P₂W₁₈O₆₂ [25], Fe(DS)₃ [26], ZrOCl₂·8H₂O/SiO₂ 
[27], trichloro-1,3,5-triazine [28], silica sulfuric acid (SSA) 
[29], sulfated zirconia [30], metal hydrogen sulfates [31]. It 
is also possible to use alternative energy sources including 
microwaves and ultrasound [32 – 34]. However, most of the 
reported methods involve toxic metal ions, corrosive and ex-
pensive reagents, and are characterized by low yield of prod-
ucts, long reaction times, tedious methods of separation of 
products, and use of environmentally harmful organic sol-
vents. Performing organic reactions under solvent-free con-
ditions has attracted much attention because of being safe, 
non-toxic, environmentally friendly, and cheap compared to 
organic solvents [35]. One of the logical solutions for the 
aforementioned problems is to use water-soluble catalyst un-
der solvent-free conditions. When a water soluble catalyst is 
used, the insoluble crude products can be separated by sim-
ple filtration and the catalyst system can be recycled.

2. RESULTS AND DISCUSSION

2.1. Chemistry

The development of drug resistance by some germs and 
the basic need in new antimicrobial compounds on one hand, 
and various activities of BIMs such as anticancer, antibacte-
rial and anti-fungal on the other hand encouraged us to study 
of the antimicrobial activity of some new BIM derivatives. In 
continuation of our research program on the development of 
new methods for the synthesis of heterocyclic derivatives, 
here, we describe the preparation of benzylsulfamic acid 
(Scheme 1) and its use as an inexpensive catalyst for the syn-
thesis of new BIMs via the condensation reaction of one

¹ Department of Chemistry, Faculty of Sciences, Islamic Azad University, 
Tonekabon Branch, Tonekabon, Iran.
² Department of Chemistry, School of Science, Alzahra University, Vanak, 
Tehran, Iran.
* e-mail: montazer1350@gmail.com
equivalent bis-aldehyde with four equivalent indoles under solvent-free conditions at 100°C (Scheme 2). The antimicrobial bacterial activity of these compounds was investigated against Gram-positive and Gram-negative species.

**Catalyst.** To initiate the study, benzylsulfamic acid was prepared by straightforward addition of one equivalent of chlorosulfonic acid to benzylamine at 0°C. The structure of benzylsulfamic acid was identified by FT-IR, $^1$H and $^{13}$C NMR, TGA, and mass spectroscopy techniques.

The presence of an additional sulfonic acid group on benzylamine nitrogen in the catalyst increases the number of vibrational modes and causes completely different FT-IR spectrum. In the FT-IR spectrum, the broad band between 2422 and 3358 cm$^{-1}$ that centered at 2959 cm$^{-1}$ can be attributed to -OH stretching of the -SO$_3$H group. Other characteristic absorption bands at 1267, 1156 and 887 cm$^{-1}$ were assigned to the asymmetric and symmetric SO$_2$ stretching, S-OH bending, and symmetric S-N stretching vibrations, respectively [37, 38]. Alternatively, in the IR spectra of catalyst, the bands at 3412 and 3334 cm$^{-1}$ disappeared and a band at 3396 cm$^{-1}$ (related to the –NH stretching of –NHSO$_3$H group) emerged. The $^1$H and $^{13}$C NMR spectra were taken in DMSO-$d_6$ solvent. Important peak in $^1$H NMR spectrum of catalyst was attributed to acidic hydrogen (SO$_3$H) and observed at $\delta = 5.64$ ppm. The acidic hydrogen of ClSO$_3$H at 13.45 ppm in the $^1$H NMR spectra of benzylamine in CDCl$_3$ was reported in literature [39]. It is noteworthy that benzylamine and ClSO$_3$H are readily soluble in CH$_2$Cl$_2$ while benzylsulfamic acid is insoluble in CH$_2$Cl$_2$ and readily soluble in water. Important peaks in the mass spectrum of the catalyst were observed at 188 (M$^+$+1), 187 (M$^+$), 186 (M$^-$H), 107 (M$^-$SO$_3$H), 92 (toluene) and 78 (benzene). The TGA curves of the catalyst were measured under nitrogen. The TGA curve indicated a weight loss below 100°C which corresponds to the loss of physically adsorbed water. Benzylsulfamic acid was degraded mainly via a two-stage process. The first weight loss observed in the vicinity of 160 – 170°C ($T_{\text{max}} = 163^\circ$C) is attributed to the loss of sulfonic acid. The second weight loss corresponding to the complete destruction of catalyst is observed in the region of 350 – 360°C. The TGA information affirms that the catalyst is stable at 160°C.

### TABLE 1. Influence of the Amount of Catalyst and Temperature on the Model Reaction

| Entry | Catalyst (mol%) | Temperature (°C) | Time (min) | Yield (%)$^a$ |
|-------|-----------------|------------------|------------|---------------|
| 1     | Non             | 90               | 120        | -             |
|       |                 | 100              | 120        | -             |
|       |                 | 110              | 120        | -             |
| 2     | 5               | 90               | 60         | 60            |
|       |                 | 100              | 55         | 75            |
|       |                 | 110              | 50         | 70            |
| 3     | 10              | 90               | 45         | 75            |
|       |                 | 100              | 38         | 82            |
|       |                 | 110              | 40         | 80            |
| 4     | 15              | 90               | 35         | 85            |
|       |                 | 100              | 30         | 98            |
|       |                 | 110              | 32         | 97            |
| 5     | 20              | 90               | 35         | 89            |
|       |                 | 100              | 32         | 98            |
|       |                 | 110              | 35         | 97            |

$^a$ Isolated yield
Synthesis of new bis(indolyl)methane derivatives. For this purpose, a model reaction of the condensation of 4,4′-(butane-1,4-diylbis(oxy))dibenzaldehyde (1 mmol) and indole (1 mmol) was carried out under solvent-free conditions in the presence of various quantities of benzylsulfamic acid at various temperatures. The results are summarized in Table 1. Excellent results were obtained in the presence of benzylsulfamic acid (Table 1, Entry 4), while in the absence of catalyst a minor product was detected (Table 1, Entry 1). Raising the amount of catalyst increased the yield of compound 3a. The optimum amount of the catalyst was 15 mol%, while a higher amount of the catalyst beyond this value did not increase the yield of 3a noticeably. Based on these results, this procedure was then extended to obtaining other bis-aldehydes and indoles in the optimized system. Thus, new BIM derivatives 3a–3f were prepared via the one-pot reaction of one equivalents bis-aldehydes with four equivalents indoles under solvent-free conditions at 100°C. The general route for the synthesis of BIM derivatives is given in Scheme 2. The review of literature showed that BIM derivatives 3a–3f have not been reported previously. The structures of new products were confirmed by FT-IR, 1H and 13C NMR, and elemental analyses.

Reusability of the catalyst was checked via the same model reaction under optimized conditions. After completion of the reaction, the catalyst was filtered after washing the reaction mixture with hot and dry ethanol, and reused in the same reaction process. As can be seen from Fig. 1, the catalyst could be reused at least four times with only small reduction in the catalytic activity.

2.2. Antibacterial Activity

All synthesized compounds 3a–3f were screened for their antibacterial activity against Pseudomonas aeruginosa (MTCC 1688), Escherichia coli (MTCC 443) and Pseudomonas oleovorans (MTCC 617) as Gram-negative bacteria, Staphylococcus aureus (MTCC 96) and Bacillus subtilis (MTCC 441) as Gram-positive bacteria. The inhibitory zones (in mm) were determined using the agar diffusion method (cup plate method). Streptomycin and DMSO were used as positive control and negative control against bacteria, respectively. All measurements were performed in duplicate and the results are reported as mean of at least three measurements.

As shown in Table 2, there is a significant difference between the antibacterial strength of synthesized compounds (3a–3f) and streptomycin antibiotics (P = 0.001). The obtained data show that the antimicrobial activity of streptomycin is higher than that of other substances. However, among synthesized compounds, compounds 3f and 3a have the highest and lowest antibacterial activity, respectively. All compounds exhibited good antibacterial activity. The significant inhibition exhibited by compounds 3c and 3f might be due to the presence of nitrile group in the fifth position of the corresponding heteroaryl rings. The results presented in Table 2 show that, among these BIMs the activity is ordered as 3f > 3c > 3b > 3e. The replacement of various groups and changes in the alkyl chain of BMIs 3a–3f also enhanced the inhibitory activity.

2.3. Antifungal Activity

As shown in Table 3, there is a significant difference between the antifungal strength of the synthesized compounds.

### Table 2. Comparison of Antibacterial Activity of Synthesized Compounds and Streptomycin (Inhibition Zone Diameter Measured in Millimeters)

| Compound | P. aeruginosa | E. coli | P. oleovorans | B. subtilis | S. aureus |
|----------|--------------|---------|--------------|-------------|----------|
| 3a       | 8 ± 1        | 8 ± 0   | 10 ± 1       | 9 ± 1       | 11 ± 1   |
| 3b       | 10 ± 0       | 10 ± 2  | 13 ± 0.5     | 11 ± 0      | 12 ± 0.5 |
| 3c       | 14 ± 1       | 12 ± 0.5| 11 ± 0       | 16 ± 1      | 12 ± 0.5 |
| 3d       | 10 ± 1       | 9 ± 0   | 10 ± 2       | 11 ± 1      | 9 ± 0    |
| 3e       | 11 ± 0       | 11 ± 1  | 11 ± 0       | 10 ± 0      | 11 ± 1   |
| 3f       | 12 ± 0.5     | 16 ± 0.5| 11 ± 0       | 18 ± 1      | 14 ± 0.5 |
| Streptomycin | 24 ± 1        | 29 ± 0.5| 29 ± 1       | 19 ± 2      | 21 ± 1   |
| Analysis | F = 53.909   | F = 598.182| F = 93.818   | F = 40.485  | F = 93.429 |
| of variance test | P = 0.001   | P = 0.001| P = 0.001    | P = 0.001   | P = 0.001 |
3. EXPERIMENTAL PART

3.1. General

Melting points were measured on Electrothermal 9100 apparatus. Chemicals were obtained from Merck and Fluka and used as purchased. The 1H NMR and 13C NMR spectra were obtained on Bruker DRX 500 Avance spectrometer using DMSO-d6 as solvent and TMS as internal standard. FT-IR spectra were recorded on Shimadzu FT-IR-8400S spectrophotometer. All bis-aldehydes (4) were prepared according to a reported method [36]. The mass spectra were obtained at 70 eV on Varian Mat CH-7 (Varian Medical Systems, Palo Alto, CA, USA). TGA analyses were performed according to a reported method [36]. The mass spectra were obtained at 70 eV on Varian Mat CH-7 (Varian Medical Systems, Palo Alto, CA, USA). TGA analyses were performed.

3.2. Synthesis

General procedure for the preparation of benzylsulfamic acid catalyst. A 25-mL suction flask charged with benzylamine (1.092 mL, 10 mmol) solution in dry CH2Cl2 (5 mL) was equipped with a constant-pressure dropping funnel containing 1.165 g (10 mmol) chlorosulfonic acid and a gas inlet tube for HCl gas flow over an adsorbing aqueous solution. Chlorosulfonic acid was added dropwise over a period of 20 min while the reaction mixture was stirred slowly on an ice-cold water bath. Then, the mixture was heated to room temperature and stirred for additional 2 h. Finally, the mixture was filtered and the solid residue was washed with dry ether (3 x 5 mL) and dried under vacuum. The catalyst was obtained as a withe-colored solid in 1.794 g (98%) yields.

General procedure for the synthesis of bis(4-(bis-(4-substituent-1H-indol-3-yl)-methyl)-phenoxy)alkanes (3a – 3f). A mixture of bis-aldehyde (1 mmol), indole derivative (4 mmol), and benzylsulfamic acid catalyst (15 mol%) was stirred at 100°C for 40 – 45 min. The process of reaction was monitored by TLC (n-hexane-EtOAc (3:1)). After completion of the reaction, the product was dissolved in hot dry ethanol (2 x 10 mL) and insoluble catalyst was removed by filtration with a filter paper. The organic phase including the product and EtOH was evaporated under vacuum. The resulting crude material was purified by recrystallization from EtOH to afford pure products. All synthesized compounds were characterized by their physical constants, FT-IR, 1H and 13C NMR spectroscopy, and elemental analysis.

3.3. Characteristics of Synthesized Compounds

Benzylsulfamic acid catalyst: white-colored solid; mp, 250 – 251°C; FT-IR (KBr, ν, cm−1): 3396 (N-H), 2422 – 3358 (O-H acidic), 1592, 1559 (C=C), 1267, 1156 (SO2); 1H NMR (400 MHz, DMSO; δ, ppm): 4.02 (d, 2H, J = 5.6 Hz), 5.64 (s, 1H), 7.35 – 4.43 (m, 3H), 7.45 – 7.48 (m, 2H), 8.23 (s, 1H); 13C NMR (100 MHz, DMSO; δ, ppm): 42.8, 134.3, 128.9, 129.0, 129.3, 130.1; MS (70 eV; m/z) 188 (M+ + 1), 187 (M+), 186 (M+-SO2H), 92 (toluene), 78 (benzene).

1,4-Bis(4-(di(1H-indol-3-yl)methyl)phenoxy)butane (3a): yield, 89%; mp, 218 – 220°C; FT-IR (KBr, ν, cm−1): 3095 (N-H), 3041 (C-H aromatic), 2938, 2868 (C-H aliph), 1604, 1459 (C=C), 1235 (C-O); 1H NMR (400 MHz, DMSO; δ, ppm): 1.85 (br, 4H), 3.95 (br, 4H), 5.77 (s, 2H), 6.80 – 6.88 (m, 16H), 7.03 (t, 4H, J = 7.2 Hz), 7.24 (d, 4H, J = 8.4 Hz), 7.35 (d, 4H, J = 8.4 Hz), 10.80 (s, 4H); 13C NMR (100 MHz, DMSO; δ, ppm): 26.0, 39.3, 67.4, 111.9, 114.3, 118.6, 118.9, 119.6, 121.3, 123.9, 129.1, 129.3, 130.1, 130.6, 131.3; Caled. for C50H42N4O2 (%): C 82.16; H 5.79; N 7.67; Found (%): C 85.19; H 5.77; N 7.64.

1,4-Bis(4-(bis-(5-bromo-1H-indol-3-yl)methyl)phenoxy)butane (3b): yield, 88%; mp, 208 – 210°C; FT-IR (KBr, ν, cm−1): 3409 (N-H), 3041 (C-H aromatic), 2938, 2868 (C-H aliph), 1604, 1459 (C=C), 1235 (C-O); 1H NMR (400 MHz, DMSO; δ, ppm): 1.83 (br, 4H), 3.97 (br, 4H), 5.77 (s, 2H), 6.82 – 6.88 (m, 16H), 7.03 (t, 4H, J = 7.2 Hz), 7.24 (d, 4H, J = 8.4 Hz), 7.35 (d, 4H, J = 8.4 Hz), 10.80 (s, 4H); 13C NMR (100 MHz, DMSO; δ, ppm): 26.0, 39.3, 67.4, 111.9, 114.3, 118.6, 118.9, 119.6, 121.3, 123.9, 129.1, 129.6, 130.7, 137.3, 157.1; Caled. for C50H41BrN4O2 (%): C 78.16; H 5.79; N 7.71; Found (%): C 81.26; H 5.79; N 7.67; Found (%): C 85.19; H 5.77; N 7.64.

### TABLE 3. Comparison of Antifungal Activity of Synthesized Compounds and Amphotericin (Inhibition Zone Diameter Measured in Millimeters)

| Compound | C. albicans | R. oryzae | A. niger |
|----------|-------------|-----------|---------|
| 3a       | 8 ± 1       | 9 ± 1     | 0       |
| 3b       | 12 ± 0.5    | 13 ± 0.5  | 0       |
| 3c       | 10 ± 2      | 12 ± 0.5  | 13 ± 0.5|
| 3d       | 11 ± 0.5    | 14 ± 0.5  | 0       |

Amphotericin B: 23 ± 2

Analysis of variance test: F = 151.538, P = 0.001; F = 424.80, P = 0.001; F = 256.727, P = 0.001.
yield: 92%; mp, 223 – 225°C; FT-IR (KBr, ene))bis(methanetriyl))tetrakis(1H-indole-5-carbonitrile) (3c): yield, 90%; mp, 214 – 216°C; FT-IR (KBr, 3422 (N-H), 3047 (C-H arom), 2936, 2867 (C-H aliph), 2218 (C=N), 1506, 1465 (C=C), 1238 (C-O); 1H NMR (400 MHz, DMSO; δ, ppm): 1.87 (s, 4H), 3.98 (br, 4H), 5.97 (s, 2H), 6.87 (m, 4H), 7.11 (s, 4H), 7.26 (d, 4H, J = 8.4 Hz), 7.43 (d, 4H, J = 8.8 Hz), 7.54 (d, 4H, J = 8.4 Hz), 7.80 (s, 4H), 11.49 (s, 4H); 13C NMR (100 MHz, DMSO; δ, ppm): 22.9, 38.1, 67.4, 100.7, 113.3, 114.6, 119.7, 121.3, 124.2, 125.0, 126.6, 126.7, 129.5, 136.2, 138.7, 157.5; Calcd. for C54H38N8O2 (%): C 78.05; H 6.42; N 5.31. Found (%): C 78.08; H 5.50; N 5.33.

3.3’,3”’-((((Butane-1,4-diybis(oxy))bis(4,1-phenylene))bis(methanetriyl))tetrakis(1H-indole-5-carbonitrile) (3d): yield, 88%; mp, 222 – 224°C; FT-IR (KBr, ν, cm⁻¹): 3409 (N-H), 3050 (C-H aryl), 2933, 2865 (C-H aliph), 1503, 1458 (C-C), 1235 (C-O); 1H NMR (400 MHz, DMSO; δ, ppm): 1.58 (m, 2H), 1.74 (m, 4H), 3.92 (t, 4H, J = 8.0 Hz), 5.75 (s, 2H), 6.79 – 6.80 (m, 12H), 7.02 (s, 4H, J = 8.4 Hz), 7.22 (t, 4H, J = 7.6 Hz), 7.26 (d, 4H, J = 6.4 Hz), 7.33 (d, 4H, J = 6.4 Hz), 10.77 (s, 4H); 13C NMR (100 MHz, DMSO; δ, ppm): 22.8, 29.0, 39.3, 67.6, 111.8, 111.8, 114.3, 118.5, 118.8, 119.6, 121.2, 123.7, 127.0, 129.6, 137.0, 157.2; Calcd. for C51H38Br4N4O2 (%): C 78.15; H 4.79; N 13.23. Found (%): C 78.15; H 4.80; N 13.21.

3.4. Antibacterial Assay

The antibacterial activity of the new bis(indolyl)methanes was determined by the well diffusion method according to Lindsay [29]. Four identical colonies from each agar plate were taken with a sterile wire loop and transferred into a tube containing 5 mL of nutrient agar. The turbidity of each suspension was corrected to attain an optical comparison to that of 0.5 turbidity McFarland standard, resulting in a suspension containing approximately 1 – 2 × 10⁸ CFU/mL. Nutrient agar plates were inoculated using streaking the swab over the entire sterile agar surface. This method was repeated via streaking two more times, rotating the plate nearly 60° each time to ensure uniform diffusion of the inoculum. As the last step, the edge of the agar was swabbed. After allowing the inoculum to dry at 25°C, 6 mm diameter wells were ready in the agar by using a sterilized cork borer. The samples (100 μg/mL) were prepared by dissolving in dimethyl sulfoxide (DMSO) and introduced into duplicate wells. The plates were incubated at 37°C for 24 h. Then, the plates were studied for bacterial growth inhibition and the inhibition zone diameter measured to within nearest millimeter. DMSO and streptomycin were used as a negative control and positive control, respectively.

Antifungal Assay

The procedure followed for antifungal bioassay was analogous to that followed for antibacterial assay, where the medium was PDA 39 g/L. All compounds were studied for their antifungal activity at a concentration 100 μg/mL by using DMSO as a solvent. DMSO did not exhibit any activity at the concentration used. The control and treated samples were kept in an incubator at 28 ± 2°C for 48 h and the inhibition zones were measured to within nearest millimeter. Three replicates were maintained for each treatment, and amphotericin B (50 μg/mL) was used as a positive control.

REFERENCES

1. M. C. Bell, P. Crowley-Nowick, H. L. Bradlow, et al., *Gynecol. Oncol.*, 78, 123 – 129 (2000).
2. J. J. Michnovicz and H. L. Bradlow, *Nutr. Cancer*, 16, 59 – 66 (1991).
3. G. R. Humphrey and J. T. Kuethe, *Chem. Rev.*, 106, 2875 – 2911 (2006).
4. K. Sujatha, P. T. Perumal, D. Muralidharan and M. Rajendran, *Indian J. Chem.*, 48, 267 – 269 (2009).
5. S. H. Benabadji, R. Wen, J. Zheng, et al., *Acta Pharmacol. Sinica.*, 25, 666 – 671 (2004).
6. G. Sivaprasad, P. T. Perumal, V. R. Prabavathy and N. Mathivanan, *Bioorg. Med. Chem. Lett.*, 16, 6302 – 6305 (2006).
7. A. Kamal, M. N. A. Khan, K. S. Reddy, et al., *J. Enzyme Inhib. Med. Chem.*, 24, 559 – 565 (2009).
8. K. R. M. Naidu, S. I. Khalivulla, S. Rasheed, et al., *Int. J. Mol. Sci.*, 14, 1843 – 1853 (2013).
9. C. Hong, G. L. Firestone and L. F. Bjelanes, *Biochem. Pharmacol.*, **63**, 1085 – 1097 (2002).
10. T. Osawa and M. Namiki, *Tetrahedron Lett.*, **24**, 4719 – 4722 (1983).
11. W. Kassouf, S. Chintharlapalli, M. Abdelrahim, et al, *Cancer Res.*, **66**, 412 – 418 (2006).
12. J. S. Glasby, *Encyclopedia of Alkaloids*, New York: Plenum Press (1975).
13. M. Kirkus, M. H. Tsai, J. V. Grazulevicius, et al., *Cancer Res.*, **66**, 412 – 418 (2006).
14. J. S. Yadav, B. V. S. Reddy, V. Sunitha and K. S. Reddy, *Adv. Synth. Catal.*, **345**, 1203 – 1206 (2003).
15. A. K. Chakraborti, S. R. Roy, D. Kumar and P. Chopra, *Green Chem.*, **10**, 1111 – 1118 (2008).
16. K. Rad-Moghadam and M. Sharifi-Kiasaraie, *Tetrahedron*, **69**, 8816 – 8820 (2009).
17. P. J. Das and J. Das, *Tetrahedron Lett.*, **53**, 4718 – 4720 (2012).
18. H. Firouzabadi, N. Iranpoor and A. A. Jafari, *J. Mol. Catal. A: Chem.*, **237**, 93 – 100 (2005).
19. K. Niknam, M. A. Zolfigol, T. Sadabadi and A. Nejati, *J. Iran. Chem. Soc.*, **3**, 318–322 (2006).
20. B. Das, R. Pal, J. Banerjee, et al., *Indian J. Chem. B.*, **44**, 327–330 (2005).
21. S. S. Sonar, S. A. Sadaphal, A. H. Kattegaonkar, et al., *Bull. Korean Chem. Soc.*, **30**, 825–828 (2009).
22. F. Shirini, M. Safarpoor Langroodi and M. Abedini, *Chem. Comm.*, **21**, 1342 – 1345 (2010).
23. N. O. Mahmoudi, M. Mohammadzadeh, and E. Biazar, *J. Sulfur Chem.*, **37**, 613 – 621 (2016).
24. A. Karam, J. C. Alonso, T. I. Gerganova, et al., *Chem. Commun.*, **45**, 7000 – 7002 (2009).
25. M. M. Heravi, K. Bakhtiari, A. Fatehi and F. F. Bamoharram, *Catal. Commun.*, **9**, 289 – 292 (2008).
26. H. Veisi, B. Maleki, F. H. Eshbala, et al., *RSC Adv.*, **4**, 30683 – 30688 (2014).
27. H. Firouzabadi, N. Iranpoor, M. Jafarpour and A. Ghaderi, *J. Mol. Catal. A: Chem.*, **253**, 249 – 251 (2006).
28. G. V. M. Sharma, J. J. Reddy, P. S. Lakshim and P. R. Krishna, *Tetrahedron Lett.*, **45**, 7729 – 7732 (2004).
29. M. A. Zolfigol, P. Salehi, M. Shiri, et al., *Mol. Divers.*, **2**, 203 – 207 (2008).
30. B. M. Reddy, P. M. Sreekanth and P. Lakshmanan, *J. Mol. Catal. A: Chem.*, **237**, 93 – 100 (2005).
31. K. Niknam, M. A. Zolfigol, T. Sadabadi and A. Nejati, *J. Iran. Chem. Soc.*, **3**, 318–322 (2006).
32. B. M. Reddy, P. M. Sreekanth and P. Lakshmanan, *J. Mol. Catal. A: Chem.*, **237**, 93 – 100 (2005).
33. M. Zahran, Y. Abdin, and H. Salama, *ARKIVOC*, **11**, 256–265 (2008).
34. B. Das, R. Pal, J. Banerjee, et al., *Indian J. Chem. B.*, **44**, 327–330 (2005).
35. S. S. Sonar, S. A. Sadaphal, A. H. Kattegaonkar, et al., *Bull. Korean Chem. Soc.*, **30**, 825–828 (2009).
36. F. Shirini, M. Safarpoor Langroodi and M. Abedini, *Chem. Comm.*, **21**, 1342 – 1345 (2010).
37. N. O. Mahmoudi, M. Mohammadzadeh, and E. Biazar, *J. Sulfur Chem.*, **37**, 613 – 621 (2016).
38. A. Karam, J. C. Alonso, T. I. Gerganova, et al., *Chem. Commun.*, **45**, 7000 – 7002 (2009).